Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: A randomized phase-II study of the Belgian Society of Medical Oncology-Reference-Cited by-同舟云学术

Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: A randomized phase-II study of the Belgian Society of Medical Oncology

Published:2010-07 Issue:1 Volume:75 Page:70-77
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Beuselinck Benoit,Wildiers Hans,Wynendaele Wim,Dirix Luc,Kains Jean-Pierre,Paridaens Robert

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference26 articles.

1. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer;Jones;J Clin Oncol,2005

2. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to Trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B Protocol 9840;Seidman;J Clin Oncol,2008

3. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer;Perez;J Clin Oncol,2001

4. Weekly paclitaxel in pretreated metastatic breast cancer: retrospective analysis of 52 patients;Baltali;Tohoku J Exp Med,2004

5. A promising second line treatment with weekly paclitaxel in anthracycline recurrent, advanced breast cancer patients;Mickiewicz;Proc Am Soc Clin Oncol,1999

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fatigue in patients with metastatic breast cancer undergoing single-agent taxane-based chemotherapy: a real-world data global network;Therapeutic Advances in Medical Oncology;2024-01

2. Breast Cancer in Geriatric Patients: Current Landscape and Future Prospects;Clinical Interventions in Aging;2022-09

3. Evidence-Based Practice Guideline for the Management of Lymphedema Proposed by the Japanese Lymphedema Society;Lymphatic Research and Biology;2022-01-03

4. A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation;Clinical Cancer Research;2021-09-13

5. Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer;Journal of Oncology;2020-11-28